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Induction of Erythroid Differentiation and Fetal Hemoglobin Production in Human Leukemic Cells Treated With Phenylacetate
By Dvorit Samid, Annie Yeh, and Premakala Prasanna
There is considerable interest in identifying nontoxic differentiation inducers for the treatment of various malignant and nonmalignant blood disorders, including inborn p-chain hemoglobinopathies. Using the human leukemic K562 cell line as a model, we explored the efficacy of phenylacetate, an amino acid derivative with a low toxicity index when administered to humans. Treatment of K562 cultures with pharmacologically attainable concentrations of phenylacetate resulted in erythroid differentiation, evident by the reduced growth rate and increased hemoglobin production. The effect was time-and dose-dependent, further augmented by glutamine starvation (phenylacetate is known to deplete circulating glutamine in vivo), and reversible upon cessation T HAS LONG BEEN recognized that pharmacologic I manipulation of the kinetics of cell growth and differentiation could benefit cancer patients.' More recently, it became apparent that similar treatments might also have a beneficial effect in patients with p-chain hemoglobinopathies, due to erythroid maturation with increased fetal hemoglobin (HbF) ~ynthesis.2~~ Several antitumor drugs, including hydroxyurea (HU), 5 -azacytidine (SAzaC), 5-aza-2'-deoxycytidine (SAzadC), vinblastine, arabinosylcytosine (ara-C), methotrexate, myleran (busulfan), and adriamycin, can increase the production of HbF in experimental mode l~.~-~ Moreover, HU and 5AzaC were shown to be active in patients with sickle cell anemia and severe p thalas~emia.~,32~-~ However, concerns regarding toxic and potential carcinogenic effects of the prevailing antitumor drugs raise the need to identify safe alternatives for long-term treatment of inborn nonmalignant diseases. The accumulation of HbF in adults is thought to be due to changes in the kinetics of erythroid differentiation rather than a direct effect on the fetal globin genes. According to this hypothesis, other agents that can induce differentiation would be expected to affect HbF production. We focus here on the efficacy of a novel nontoxic differentiating agent, phenylacetate. Phenylacetate is a naturally occurring plasma component capable of conjugating glutamine to yield phenylacetylglutamine (PAG), which is subsequently excreted in the urine.10 The latter, leading to waste nitrogen excretion, has
The publication costs of this article were defrayed in part by page charge payment. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S. been the basis for using sodium phenylacetate (NaPA) in the treatment of hyperammonemia associated with inborn errors of urea synthesis"J2 or liver fai11.1re.I~ Clinical experience indicates that acute or long-term treatment with high doses of NaPA (250 to 550 mg/kg/d, plasma levels 3 to 6 mmol/L) is well tolerated by both infants and adults, essentially free of adverse effects, and effective in reducing plasma glutamine levels. The lack of toxicity of NaPA is not limited to individuals with these metabolic disorders, as documented with normal volunteer^.^^ Our laboratory has recently found that NaPA, when used at the pharmacologic concentrations, can affect the maturation of various animal and human cell types in vitro without affecting cell viability. For example, treatment of promyelocytic leukemia HL-60 cells resulted in the rapid decline of myc oncogene expression followed by growth arrest and granulocyte differentiation.15 Phenylacetate also induced highly efficient adipocyte conversion in mesenchymal C3H lOTl/2 cultures. Unlike the differentiating chemotherapeutic SAzadC, phenylacetate was neither cytotoxic nor did it cause neoplastic transformation in susceptible ~e1ls.I~ The lack of toxicities and the ability to induce cellular differentiation prompted us to examine the effect of NaPA on erythroid maturation and HbF biosynthesis. The experimental system involved the human leukemic K562 cells, which carry a nonfunctional p globin gene, but produce low levels of the fetal y globin and of HbF.16J7 The K562 cell line was originally established from a patient with chronic myelogenous leukemia in the blast cell transformation,ls and has since been extensively used as a model in studies of erythroid differentiation and regulation of y globin gene expression. We show here for the first time that pharmacologically attainable concentrations of NaPA can promote HbF biosynthesis in human cells, and can cause superinduction when combined with other chemotherapeutic agents of interest, ie, HU, SAzaC, and 5AzadC. MO) , and PAG (BRI, Houston, TX) were dissolved in distilled water, and brought to pH 7.0 by the addition of NaOH. SAzadC, SAzaC, and HU (Sigma) were also dissolved in distilled water. All drug stock solutions were stored in aliquots at -20°C until used.
MATERIALS AND METHODS

Cell
K562 cells were seeded at 1 X lo5 cells/mL and treated with the drugs for 4 to 7 days before assay. Qualitative estimation of Hb production was determined by benzidine staining of intact cells in suspension." The Hb concentration within cells was determined by the protein absorption at 414 nm. Briefly, 1 x 10' cells were lysed in 1 mL of lysing buffer (0.12% Tris, pH 7.4,0.8% NaCI, 0.03% Mg-acetate, and 0.5% NP-40), vortexed, and incubated on ice for 15 minutes. The lysate were then centrifuged for 15 minutes at 1,500 rpm at 4"C, and the absorption of the supernatant monitored between 350 nm and 650 nm using a Du-7 scanning spectrophotometer (Beckman Instruments Inc, Fullerton, CA). The Hb was quantitated considering that optical density (OD) of 1.0 at 414 nm corresponds to 0.13 mg/mL Hb.
Newly synthesized proteins were labeled with 35S-methionine, and the HbF was immunoprecipitated and analyzed as previously described." Briefly, 1 x lo6 cells/mL were first subjected to 30 minutes of starvation in methionine-free medium and then incubated in the presence of 100 p,Ci/mL of 35S-methionine (ICN Radiochemicals, Irvine, CA) for 2 hours. The labeled cells were harvested, washed, and lysed in a lysing buffer containing 10 mmol/L phosphate buffer, pH 7.4,1% Triton X100, 0.1% sodium dodecyl sulfate (SDS), 0.5% deoxycholate, 100 mmol/L NaC1, 0.1% NaN3,2 mmol/L phenylmethylsulfonyl fluoride, 20 p,g/mL aprotinin, and 10 p,g/mL leupeptin. trichloroacetic acid (TCA)-precipitable count of cytoextract (1 x 10' cpm) was incubated with rabbit antihuman HbF antibody (New England Immunology Associates, Cambridge, MA) and protein A Sepharose (Pharmacia Inc, Piscataway, NJ) at 4"C, and the immunoprecipitates were separated by electrophoresis on 12% SDS-polyacrylamide gels. Gels were dried and exposed to Kodak X-OMAT AR film (Eastman Kodak, Rochester, NY) at -70°C. Densitometry of autoradiograms was performed using Datacopy Scanner model 230M (Xerox Imaging Systems, Peabody, MA).
Cytoplasmic RNA was prepared from cultures at logarithmic phase of growth and separated on l % agarose-formaldehyde gels. RNA isolation, gel electrophoresis, transfer onto Nytran membranes (Schleicher & Schuell, Inc, Keene, NH), hybridization with radiolabeled DNA probes, and autoradiography (Kodak X-ray film XARS) were described.21 Probes were labeled with [32P]dCTP (New England Nuclear, Boston, MA) using a random primed DNA labeling kit (Boehringer Mannheim, Mannheim, Germany). The 0.6-kb EcoRI/ Hind111 fragment of the 3' end of human G y-globin gene was used to probe for y globin messenger RNA (mRNA). Hybridization with glyceraldehyde phosphate dehydrogenase (GAPDH) cDNA served as internal control to evaluate the relative amounts of total RNA loaded onto gels. Quantitation of globin mRNA in treated versus control cells was by densitometric analysis of autoradiograms of hybridized blots, using the Datacopy Scanner (see above). Results were normalized based on the corresponding GAPDH signal.
Determination of Hbproduction.
Immunoprecipitation of HbF protein.
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RESULTS
The effect of NaPA and analogues on cell growth and differentiation. Treatment of K562 cultures with NaPA resulted in dose-dependent inhibition of cell proliferation, with the IC50 being approximately 8 mmol/L (Fig 1) . No toxicity was observed with concentrations as high as 12 mmol/L (cell viability monitored during the first 5 days of treatment was more than 95%). In addition to the cytostatic effect, NaPA induced erythroid differentiation, as evident by the increased number of benzidine-positive cells (Fig 1) and confirmed by quantitative analysis of Hb production ( Table 1 ). The effect of NaPA on cell growth and differentiation was dependent on continuous presence of the drug; upon cessation of treatment, there was a gradual decline in Hb and increased growth rate, reaching control levels after about 2 weeks. The effect of NaPA on Hb production could be mimicked by the analogue 4-hydroxyphenylacetate (4HPA) ( Table 1) . Both NaPA and 4HPA are known to conjugate glutamine in humans.I0 By contrast, the glutamine-conjugated form, ie, PAG, had no significant effect on either cell proliferation or Hb accumulation. Two other analogues, 3,4-dihydroxyphenylacetate (3,4dHPA) and 2,5-dihydroxyphenylacetate (2,5dHPA), were found to be highly cytotoxic (LDS0 of 0.35 Regulation of HbF hy NaPA. K562 cells normally express low but detectable levels of HbF. Protein analysis using anti-HbF antibodies showed that the increase in total Hb in NaPA-treated cells, measured by protein absorbance, was largely due to induction of HbF. Quantitative analysis by densitometry showed an approximately fourfold increase in the amounts of HbF in cells treated with NaPA 10 mmol/L compared with untreated controls (Fig 2A) . The latter was associated with similarly elevated steady-state levels of fetal y globin mRNA (Fig 2B) . indicating a pretranslational regulation.
In humans, NaPA causes depletion of circulating glutaminel* due to conjugation of the amino acid to form PAG, an enzymatic reaction known to take place in the liver and kidney.'" The in vivo reduction in plasma glutamine levels was mimicked in vitro by culturing the K562 cells in the presence of lowered glutamine concentrations. In agreement with a previous glutamine starvation alone affected K562 growth rate (not shown) and Hb production (Fig 3) ; the effect was further augmented by the addition of NaPA 5 mmol/L. We speculate therefore that, in humans, NaPA may induce erythroid differentiation and HbF production through both depletion of circulating glutamine and a direct effect on erythroid progenitor cells.
Cooperative induction of HbF by NaPA and other chemotherapeutic dnrgs. Despite promising activities of HU,
SAzaC, and SAzadC in sickle cell anemia, B thalassemia, and numerous malignancies, their clinical usefulness has been hindered by unacceptable toxicities? Combinations with a nontoxic differentiating agent such as NaPA could enhance the efficacy while minimizing the adverse effects of toxic chemotherapies. As shown in Table 2 , the addition of NaPA to suboptimal doses of either HU or the cytidine analogues resulted in efficient erythroid differentiation (evident by the increased number of benzidine-positive cells and Hb accumulation) without affecting cell viability. By immunoprecipitation with anti-HbF antibodies (Fig 4) was shown that the Hb data presented in Table 2 reflect on the accumulation of the fetal form of Hb. While HbF levels increased 2.96-fold by NaPA 5 mmol/L and 4.61-fold by HU 100 pmol/L, cells treated with both drugs had 11.8-fold more HbF than untreated controls. Taken together, results indicate that NaPA and HU may act synergistically to induce HbF production in K562 cells. The combination of NaPA and SAzaC/SAzadC had an additive effect. Further studies, summarized in Fig 5, showed that glutamine depletion markedly enhanced the Hb production in cells treated by NaPA in combination with HU, SAzaC, or 5AzadC. In all cases, cell viability was greater than 95%.
DISCUSSION
Differentiating agents selected for their low cytotoxic/ carcinogenic potential could be of value for long-term treatment of various blood disorders. Drug toxicity is a particularly important consideration in the case of severe inborn anemias, in view of the overall health condition and the variable life-span of patients. To date, several therapeutic agents have been evaluated for safety and efficacy. Recombinant human erythropoietin, which proved nontoxic and effective in treatment of anemia associated with chronic renal disease," was unfortunately found to be ineffective in sickle cell anemia." The application of SAzaC, an antitumor agcnt with impressive activity in sickle cell disease, has bccn hindered by conccrns regarding its carcinogenic potentiaL3 Another active drug, HU, is difficult to use because of the narrow margin bctwcen toxicity and the desired effect on HbF production.ls By contrast, NaPA, shown here to induce erythroid differentiation and HbF production in vitro, is neither cytotoxic nor carcinogenic at effective concentration^^^ (data presented here, in Samid et al,Is and in Samid et al, manuscript in preparation). The lack of toxicity to humans has long been established. Studies dating back to 1933 documented that administration of phenylacetate 5 to 10 g to humans for 28 days is free of ~idc-effects.~~ More recent experience with patients suffering from urea cycle disorders indicates that the drug is so wcll tolerated that chronic treatment can be initiated just a few hours after birth.26
Using human leukemic K562 cells as a model, it was shown that NaPA can promote the maturation of erythroid progenitor cells that have an active HbF program. The analogue 4HPA was found to be similarly effective, whereas other analogues, including PAG, 3.4dHPA, or 2,SdHPA. were inactivc. The accumulation of HbF in NaPA-trcated cells was associated with elevated levels of y globin mRNA. NaPA, which was shown to cause hypomethylation in plant2' and murine cells (our unpublished data), could act through demethylation of y globin genes. This hypothesis is currently under investigation. Alternatively, the increase in HbF production may be secondary to a reversiblc block of cell cycle and a change in the kinetics of cell maturation. Indeed, the kinetics of erythroid maturation induced by NaPA resembles that observed with cell-cycle drugs such as SAzaC, vinblastinc, and ara-C! In humans, NaPA (as well as 4HPA) may induce erythroid diffcrentiation also through binding to, and depletion of, circulating g1utamine.I'' Glutamine is the major nitrogen source for nucleic acid and protein synthesis, and the substrate for energy in rapidly dividing malignant and nonmalignant cells of the erythroid lineagc.w.29 Glutamine starvation can block cclls in the G1 phase of growth and accelerate the kinetics of differentiation. In patients with elevated plasma glutamine levels (1.08 mmol/Lv0.5 2 0.17 mmol/L in controls), NaPA treatment caused a reduction to 0.1 to 0.2 mmol/L.'? The enzymatic reaction leading to glutamine deplction takes place in thc mitochondria of liver and kidney cclls,10 and may not occur in leukemic cells treated in vitro.15 To mimic the in vivo effect, K562 cells were cultured in medium containing lowered amounts of glutaminc. In agreement with prcvious observations,u glutamine starvation alone was sufficient to trigger erythroid differentiation with elevated production of Hb. an effcct that was further enhanced by the addition of NaPA.
NaPA potentiated the activity of HU, SAzaC, and SAzadC in K562 cclls. With combination treatments, high levels of HbF may be reached using low doses of toxic drugs. Thus far, attempts wcre made to achieve such a goal by using the combination of HU with the nontoxic agent erythropoietin in thc treatment of sickle cell disease. However, while studiesconfirmed the efficacy of HU, erythropoietin (whether used alone or in combination with HU) showed no activity.24 The addition of NaPA to HU caused marked induction of HbF synthesis under conditions in which each drug alone produced only a small effect. the results suggesting that the two agents act in a synergistic manner. The concentrations of HU used in our studics are similar to the plasma levels measured in sickle cell anemia patients after an oral administration of 25 mg/kg.24.15 This dose, compared with the more effective HU dosage used in humans (50 to 100 mg/kg), causes significantly less marrow/ hematopoietic toxicity. According to the experimental data, rather high doses of NaPA (millimoles per liter) might be needed to induce significant amounts of HbF. We speculate that such concentrations may be achieved in humans with no significant adverse effects. Pharmacokinetics studies in children with urea cycle disorders"J2 showed that phenylacetate plasma levels of 3 to 6 mmol/L are essentially toxicity free. Moreover, in one case involving Reye's syndrome, the patient did remarkably well after phenylacetate blood levels reached 10 to 19 mmol/L (Brusilow SW, personal communication, November 1991). However, there is a need for further pharmacokinetics and toxicology studies in patients that do not suffer from such metabolic disorders.
The combination of NaPA with SAzaC/SAzadC, although not as effective as that with HU, warrants special consideration. The cytosine analogues can benefit patients with l e~k e m i a~~,~~ as well as those with @-chain hemoglobin~p a t h i e s .~,~ 5AzaC was shown to be active in both sickle cell anemia and @ thalassemia, and proved less cytotoxic and more effective than HU in stimulating HbF production. The profound effect of 5AzaC (or 5AzadC) is thought to be due to its ability to perturb erythropoiesis and to inhibit DNA m e t h y l a t i~n .~~ Hypomethylation can lead to gene activation and cell differentiation; however, it can also promote oncogenesis and the evolution of cells with metastatic capabilities.zOJ1 Our experimental data suggest that NaPA could enhance differentiation and prevent neoplastic transformation induced by the cytosine analogues (Prasanna et al, manuscript in preparation).
In conclusion, it appears that NaPA, acting through glutamine depletion and other yet unidentified cellular mechanisms, may induce differentiation in human leukemic cells, promote the production of erythrocytes expressing HbF, and enhance the efficacy of other antitumor drugs while minimizing their adverse effects. NaPA, which has an unpleasant odor, can be substituted by its pro-drug, sodium phenylbutyrate (NaPB), for oral administration.26 Upon ingestion by humans, phenylbutyrate undergoes @-oxidation to phenyla~etate.~~ Both NaPA and NaPB already proved safe for the treatment of infants and a d~l t s . '~,~ It seems important therefore to further evaluate the clinical relevance of our experimental data.
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NOTE ADDED IN PROOF
Since the submission of this manuscript, 15 patients with urea cycle disorders treated with phenylbutyrate were examined for the percentage of red blood cells containing fetal hemoglobin (F cells). The mean percentage of F cells in these patients was significantly higher than that in normal subjects. 34 The data lend further support for the proposed use of phenylbutyrate and its active metabolite, phenylacetate, in treatment of p globin hemoglobinopathies.
